Silexion Therapeutics Corp. — Form 8-K Summary
Reporting date: September 28, 2026; the report was signed September 29, 2026. The filing concerns a warrant inducement transaction, not a period of operating or financial results.
Transaction and financial impact
- Holders agreed to exercise 3,216,928 existing Series E warrants for cash at a reduced price of $0.2603 per share. The company expects approximately $0.84 million in gross proceeds, before placement-agent fees and other expenses. Net proceeds were not stated; the company expects to use them for general corporate purposes.
- The placement agent is entitled to fees totaling 8% of gross proceeds from the existing-warrant exercises, plus up to $25,000 for legal and other expenses and $5,000 in clearing fees.
- In exchange, the company will issue Series F and Series G warrants covering up to 6,433,856 ordinary shares, exercisable at $0.2603 per share. Series F warrants expire five years after the later of specified share-authorization and registration milestones; Series G warrants expire after 24 months.
- The company is also reducing the exercise price of all outstanding Series E warrants covering 3,846,161 shares to $0.2603 per share. The filing does not quantify potential proceeds from future exercises of those other warrants.
- The company will issue the placement agent warrants covering up to 225,185 shares at $0.3254 per share. Additional placement-agent fees and warrants may apply in certain circumstances if the new warrants are exercised for cash.
Changes, dilution and liquidity
- The existing Series E warrants had a $0.65 exercise price; the inducement exercise price and the revised exercise price for all outstanding Series E warrants are $0.2603.
- The new warrants and placement-agent warrants create potential additional share issuance. The filing does not provide a quantified estimate of dilution as a percentage of shares outstanding.
- New warrants are not listed, and the company does not expect an active trading market to develop. They have no ordinary-share voting rights before exercise, subject to the warrant terms.
- The filing provides no revenue, profit, cash-flow, margin, debt, liquidity-balance or comparable-period metrics. It does not provide a clear value for the transaction’s net proceeds.
Conditions, obligations and risks
- Closing was expected on or about September 29, 2026, subject to customary conditions; the filing does not confirm that closing occurred.
- Exercise of the new warrants is subject to shareholder approval and an increase in authorized ordinary shares. The company also agreed to file a resale registration statement within 30 days and use commercially reasonable efforts to obtain effectiveness within 60 days, or 90 days in the event of SEC full review.
- The new warrants permit cashless exercise if a resale registration statement is not effective or available, and include ownership limits, adjustment provisions and rights upon specified fundamental transactions.
- The company agreed, subject to exceptions, not to issue shares or share equivalents or file another registration statement for 15 days after closing, and not to enter into a variable-rate transaction for one year after closing.
- The new and placement-agent warrants and related shares are unregistered securities. The filing warns that the expected closing is conditional and forward-looking statements may not be realized.
Key facts for investors to verify
- Whether the transaction closed and the company received the expected gross proceeds.
- Actual fees and expenses, and the resulting net proceeds.
- Whether shareholders approved the authorized-share increase and the timing and effectiveness of the resale registration statement.
- The final number of shares issued or issuable under the reduced-price Series E warrants, new warrants and placement-agent warrants, and the resulting dilution.
- The company’s current cash, debt, operating results and cash runway, which are not reported in this 8-K.